Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

This study has been terminated.
(Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents)
Information provided by (Responsible Party):
Takeda Identifier:
First received: September 18, 2007
Last updated: May 23, 2012
Last verified: May 2012
The purpose of the study is to determine the reduction of LDL-cholesterol level after treatment with 50 mg per day of lapaquistat acetate once daily (QD).

Condition Intervention Phase
Drug: Lapaquistat acetate
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg vs Placebo in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]

Secondary Outcome Measures:
  • Change from Baseline in Total Cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in High Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in Very Low Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in apolipoprotein A1 Timeframe: Week 12 or Final Visit [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in apolipoprotein B [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in non- High Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B [ Time Frame: Week 12 or Final Visit ]
  • Change from Baseline in Triglycerides [ Time Frame: Week 12 or Final Visit ]

Enrollment: 657
Study Start Date: October 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lapaquistat Acetate 50 mg QD Drug: Lapaquistat acetate
Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
Other Name: TAK-475
Placebo Comparator: Placebo QD Drug: Placebo
Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.

Detailed Description:
This study is being conducted to determine the potential of lapaquistat acetate 50 mg per day to lower LDL-C levels compared with placebo. This study is also being conducted to further evaluate the safety and tolerability of lapaquistat acetate 50 mg over a period of 12 weeks. An optional, 48-week, open-label extension will follow the 12 week, double-blind treatment period to evaluate the long-term safety and tolerability of lapaquistat acetate 50 mg/day.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose.
  • Prior to Randomization, the participant has a mean low density lipoprotein cholesterol level greater than or equal to 130 mg/dL and less than or equal to 190 mg/dL for 2 consecutive samples.
  • Prior to Randomization, the subject has mean triglyceride level greater than or equal to 400 mg/dL for 2 consecutive samples.
  • Is willing and able to comply with the recommended, standardized diet.

Exclusion Criteria:

  • Has an nine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, identified during screening.
  • Has a serum creatinine greater than 133 mmol/L, identified during screening.
  • Has a creatine kinase greater than 3 times the upper limit of normal, identified during screening.
  • Has active liver disease or jaundice.
  • Has taken any fibrates within 42 days of Visit 1 or any lipid-lowering therapy for at least 30 days prior to Screening.
  • Has a previous history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.
  • Has an endocrine disorder, such as Cushing's syndrome, hyperthyroidism, or inappropriately treated hypothyroidism affecting lipid metabolism.
  • Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary angioplasty, coronary or peripheral arterial surgery, or multiple risk factors that confer a 10-year risk for cardiovascular heart disease greater than 20% based on Framingham risk scoring.
  • Has a positive hepatitis B surface antigen or hepatitis C virus antibody test, as determined by medical history.
  • Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
  • Has received any investigational medication 30 days prior to screening, (for drugs with a long half-life, within a period of less than 5 times the drug's half-life) or is participating in an investigational study.
  • Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.
  • Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.
  • Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).
  • Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
  • Has uncontrolled hypertension
  • Has had inflammatory bowel disease or any other malabsorption syndrome, or has had gastric bypass or any other surgical procedure for weight loss.
  • Has a history of drug abuse or a history of high alcohol intake within the previous 2 years.
  • Has type 1 or 2 diabetes mellitus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00532558

  Hide Study Locations
Tallinn, Estonia
Tartu, Estonia
Balatonfured, Hungary
Budapest, Hungary
Debrecen, Hungary
Pecs, Hungary
Szekszárd, Hungary
Érd, Hungary
Beer Sheva, Israel
Hadera, Israel
Haifa, Israel
Jerusalem, Israel
Kfar-Saba, Israel
Nahariya, Israel
Safed, Israel
Tel Aviv, Israel
Daugavpils, Latvia
Kuldiga, Latvia
Riga, Latvia
Amsterdam, Netherlands
Breda, Netherlands
GA Nijmegen, Netherlands
Groningen, Netherlands
Hoorn, Netherlands
Rotterdam, Netherlands
Utrecht, Netherlands
Zoetermeer, Netherlands
Elverum, Norway
Hamar, Norway
Kongsberg, Norway
Oslo, Norway
Ålesund, Norway
Russian Federation
Moscow, Russian Federation
Saratov, Russian Federation
St. Petersburg, Russian Federation
Tyumen, Russian Federation
Volgograd, Russian Federation
Bratislava, Slovakia
Dolný Kubín, Slovakia
Kosice, Slovakia
Nitra, Slovakia
Nové Mesto Nad Váhom, Slovakia
Trebišov, Slovakia
Cordoba, Spain
Madrid, Spain
Pontevedra, Spain
REUS (Tarragona), Spain
Valencia, Spain
Dnepropetrovsk, Ukraine
Kharkiv, Ukraine
Kharkov, Ukraine
Kiev, Ukraine
Kyiv, Ukraine
Lutsk, Ukraine
Lviv, Ukraine
United Kingdom
Belfast, United Kingdom
Bolton, United Kingdom
Glasgow, Scotland, United Kingdom
Oldham, United Kingdom
Paignton, Devon, United Kingdom
Sheffield, United Kingdom
Sponsors and Collaborators
Study Director: Medical Director Takeda
  More Information

Responsible Party: Takeda Identifier: NCT00532558     History of Changes
Other Study ID Numbers: TAK-475_306
U1111-1122-8417 ( Registry Identifier: WHO )
Study First Received: September 18, 2007
Last Updated: May 23, 2012

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on May 25, 2017